Horizon Inks $75M AstraZeneca Deal for Genome-Editing Tech
By Nuala Moran
Monday, April 22, 2013
LONDON Horizon Discovery Ltd. is in line for undisclosed up-front and milestone payments, followed by a potential $75 million from AstraZeneca plc in a deal that signals a move-up for the company, from providing services and products to applying its genome-editing technology in-house to uncover novel targets.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.